Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 739

1.

Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine.

Ferrier-Rembert A, Drillien R, Tournier JN, Garin D, Crance JM.

Vaccine. 2008 Mar 25;26(14):1794-804. doi: 10.1016/j.vaccine.2007.12.059. Epub 2008 Feb 12.

PMID:
18336966
2.

The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.

Coulibaly S, Brühl P, Mayrhofer J, Schmid K, Gerencer M, Falkner FG.

Virology. 2005 Oct 10;341(1):91-101.

3.

Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.

Meseda CA, Garcia AD, Kumar A, Mayer AE, Manischewitz J, King LR, Golding H, Merchlinsky M, Weir JP.

Virology. 2005 Sep 1;339(2):164-75.

4.

Safety, immunogenicity and protective efficacy in mice of a new cell-cultured Lister smallpox vaccine candidate.

Ferrier-Rembert A, Drillien R, Meignier B, Garin D, Crance JM.

Vaccine. 2007 Nov 28;25(49):8290-7. Epub 2007 Oct 11.

PMID:
17964011
5.

Intranasal cowpox virus infection of the mouse as a model for preclinical evaluation of smallpox vaccines.

Ferrier-Rembert A, Drillien R, Tournier JN, Garin D, Crance JM.

Vaccine. 2007 Jun 15;25(25):4809-17. Epub 2007 Apr 24.

PMID:
17499401
6.

Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.

Berhanu A, Wilson RL, Kirkwood-Watts DL, King DS, Warren TK, Lund SA, Brown LL, Krupkin AK, Vandermay E, Weimers W, Honeychurch KM, Grosenbach DW, Jones KF, Hruby DE.

J Virol. 2008 Apr;82(7):3517-29. doi: 10.1128/JVI.01854-07. Epub 2008 Jan 16.

7.

Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine.

Phelps AL, Gates AJ, Hillier M, Eastaugh L, Ulaeto DO.

Vaccine. 2007 Jan 2;25(1):34-42. Epub 2006 Aug 1.

PMID:
16950548
8.

Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination.

Grosenbach DW, Jordan R, King DS, Berhanu A, Warren TK, Kirkwood-Watts DL, Tyavanagimatt S, Tan Y, Wilson RL, Jones KF, Hruby DE.

Vaccine. 2008 Feb 13;26(7):933-46. doi: 10.1016/j.vaccine.2007.11.095. Epub 2007 Dec 26.

9.

Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.

Wyatt LS, Earl PL, Eller LA, Moss B.

Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4590-5. Epub 2004 Mar 11.

11.

[Development of a numerically additive combined vaccine against tetanus and smallpox].

Mayr A, Baljer G, Wagner C, Sailer J.

Zentralbl Bakteriol Mikrobiol Hyg A. 1985 Apr;259(2):206-18. German.

PMID:
2990123
12.

Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.

Paran N, Suezer Y, Lustig S, Israely T, Schwantes A, Melamed S, Katz L, Preuss T, Hanschmann KM, Kalinke U, Erez N, Levin R, Velan B, Löwer J, Shafferman A, Sutter G.

J Infect Dis. 2009 Jan 1;199(1):39-48. doi: 10.1086/595565.

13.

Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses.

Belyakov IM, Earl P, Dzutsev A, Kuznetsov VA, Lemon M, Wyatt LS, Snyder JT, Ahlers JD, Franchini G, Moss B, Berzofsky JA.

Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9458-63. Epub 2003 Jul 17.

14.

Mucosal immunization induces a higher level of lasting neutralizing antibody response in mice by a replication-competent smallpox vaccine: vaccinia Tiantan strain.

Lu B, Yu W, Huang X, Wang H, Liu L, Chen Z.

J Biomed Biotechnol. 2011;2011:970424. doi: 10.1155/2011/970424. Epub 2011 Jun 20.

15.

One time intranasal vaccination with a modified vaccinia Tiantan strain MVTT(ZCI) protects animals against pathogenic viral challenge.

Yu W, Fang Q, Zhu W, Wang H, Tien P, Zhang L, Chen Z.

Vaccine. 2010 Feb 25;28(9):2088-96. doi: 10.1016/j.vaccine.2009.12.038. Epub 2009 Dec 30.

PMID:
20045097
16.

Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens.

Sakhatskyy P, Wang S, Zhang C, Chou TH, Kishko M, Lu S.

Virology. 2008 Feb 5;371(1):98-107. Epub 2007 Oct 24.

17.

Evaluation of smallpox vaccines using variola neutralization.

Damon IK, Davidson WB, Hughes CM, Olson VA, Smith SK, Holman RC, Frey SE, Newman F, Belshe RB, Yan L, Karem K.

J Gen Virol. 2009 Aug;90(Pt 8):1962-6. doi: 10.1099/vir.0.010553-0. Epub 2009 Apr 1.

18.

Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines.

Drexler I, Staib C, Kastenmuller W, Stevanović S, Schmidt B, Lemonnier FA, Rammensee HG, Busch DH, Bernhard H, Erfle V, Sutter G.

Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):217-22. Epub 2002 Dec 23.

19.

An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection.

Morikawa S, Sakiyama T, Hasegawa H, Saijo M, Maeda A, Kurane I, Maeno G, Kimura J, Hirama C, Yoshida T, Asahi-Ozaki Y, Sata T, Kurata T, Kojima A.

J Virol. 2005 Sep;79(18):11873-91.

20.
Items per page

Supplemental Content

Write to the Help Desk